ICHR
Ichor Holdings, Ltd.
ICHR has slightly lower modeled downside risk, despite its lower overall score.
SNDK
Sandisk Corporation
SNDK has the edge over ICHR overall, supported by stronger valuation and stronger fundamentals.
ICHR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Weak | |
| Strong |
ICHR's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
SNDK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
SNDK's revenue, profitability, cash flow and balance sheet are all currently strong.
ICHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $37.07 | — |
| Cheap | 13x | $0.63 | -98% |
| Fair | 20x | $1.01 | -97% |
| Expensive | 42x | $2.11 | -94% |
| Current | 741x | $37.07 | — |
Historical ranges are pointers, not guarantees.
ICHR's PE is in its expensive range at 741x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
SNDK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.8x | $937 | — |
| Current | 7.5x | $937 | — |
| Cheap | 17x | $2,173 | +132% |
| Fair | 24x | $3,048 | +225% |
| Expensive | 59x | $7,452 | +695% |
Historical ranges are pointers, not guarantees.
SNDK has the edge over ICHR in the historical PE scenario, which offers more potential upside but is not a forecast.
ICHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for ICHR, with profitability improving.
SNDK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| High |
Analysts expect strong earnings and revenue growth for SNDK, with profitability improving.
ICHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.17 | +6237% |
| Q3 2026 | $0.05 | +$1.24 |
| Q2 2026 | -$1.17 | -$0.57 |
| Q1 2026 | -$1.48 | -$1.01 |
| Q4 2025 | -$1.54 | -$0.90 |
| Q3 2025 | -$1.19 | -$0.26 |
| Q2 2025 | -$0.60 | +$0.61 |
| Q1 2025 | -$0.47 | +$1.30 |
| Q4 2024 | -$0.64 | +$0.83 |
ICHR has returned to profit: it earned $0.05 per share over the past year, after losing money the year before.
SNDK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $247.30 | +97% |
| Q3 2026 | $125.61 | +$137.63 |
| Q2 2026 | $73.76 | +$85.07 |
| Q2 2025 | -$11.31 | -$6.65 |
SNDK has the edge over ICHR in the latest year-over-year earnings comparison.
ICHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $328.7M | +37% |
| Q2 2026 | $294.8M | +23% |
| Q1 2026 | $256.1M | +4.7% |
| Q4 2025 | $223.6M | -4.2% |
| Q3 2025 | $239.3M | +13% |
| Q2 2025 | $240.3M | +18% |
| Q1 2025 | $244.5M | +21% |
| Q4 2024 | $233.3M | +15% |
ICHR's revenue is growing: $329M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.9% | +15 points |
| Q2 2026 | 2.4% | +4.4 points |
| Q1 2026 | 0.8% | +1.3 points |
| Q4 2025 | -6.2% | -5.7 points |
| Q3 2025 | -8.1% | -7.9 points |
| Q2 2025 | -2% | -0.9 points |
| Q1 2025 | -0.5% | +1.4 points |
| Q4 2024 | -0.5% | +3.4 points |
ICHR's operating margin was 6.9% last quarter, up 15 points from the same quarter a year ago.
SNDK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11B | +378% |
| Q2 2026 | $9B | +372% |
| Q1 2026 | $6B | +251% |
| Q4 2025 | $3B | +61% |
| Q3 2025 | $2.3B | +23% |
| Q2 2025 | $1.9B | +8% |
| Q1 2025 | $1.7B | -0.6% |
| Q4 2024 | $1.9B | +13% |
SNDK has the edge over ICHR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 80% | +72 points |
| Q2 2026 | 78% | +78 points |
| Q1 2026 | 69% | +180 points |
| Q4 2025 | 35% | +25 points |
| Q3 2025 | 7.6% | -9 points |
| Q2 2025 | 0.9% | N/A |
| Q1 2025 | -111% | -122 points |
| Q4 2024 | 10% | +6.6 points |
SNDK has the edge over ICHR on profitability, with a higher operating margin.
ICHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.5M | -1983% |
| Q2 2026 | -$23.6M | -$8.8M |
| Q1 2026 | -$10M | -2113% |
| Q4 2025 | $5.9M | +$12.8M |
| Q3 2025 | $2.1M | -3.3% |
| Q2 2025 | -$14.8M | -201% |
| Q1 2025 | $496K | +58% |
| Q4 2024 | -$6.9M | -119% |
ICHR's free cash flow was −$67M over the past year, against −$19M the year before.
SNDK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.3B | +1340% |
| Q2 2026 | $7.1B | +14355% |
| Q1 2026 | $3B | +$3B |
| Q3 2025 | $438M | +$636M |
| Q2 2025 | $49M | +$217M |
| Q1 2025 | -$18M | +$23M |
| Q3 2024 | -$198M | -$157M |
SNDK has the edge over ICHR on cash generation, producing positive trailing cash flow while its opponent burns cash.
ICHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.1% | +1.9M shares |
| 1 year | +11% | +3.8M shares |
| 3 years | +30% | +8.9M shares |
| 5 years | +31% | +9.1M shares |
| Available history | +67% | +15.4M shares |
ICHR has 38M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
SNDK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1M shares |
| 1 year | +3.4% | +5M shares |
| 3 years | +6.9% | +10M shares |
SNDK has the edge over ICHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5B |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
ICHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.9x | Net Cash |
| Q2 2026 | -16.3x | Net Cash |
| Q3 2025 | 6.5x | High |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.9x | Very low |
| Q3 2024 | 0.8x | Very low |
| Q2 2024 | 1.1x | Healthy |
ICHR has the edge over SNDK on leverage, with a lower net debt burden relative to earnings.
SNDK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
SNDK has more cash than debt.
ICHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 10.0 | Oversold |
ICHR's weekly RSI is 38 (neutral) and its Stochastic is 10 (oversold).
SNDK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.2 | Neutral |
| Stochastic | 10.6 | Oversold |
SNDK's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
ICHR PE vs Technology Sector
| Metric | ICHR | Sector median | Relative |
|---|---|---|---|
| PE | 741x | 28x | 2,561% above |
| PE % | 100 | 35 | 65 pts above |
ICHR is trading at 741x earnings, a 2561% premium to the Technology sector's median of 28x.
SNDK PE vs Technology Sector
| Metric | SNDK | Sector median | Relative |
|---|---|---|---|
| PE | 7.5x | 28x | 73% below |
| PE % | 4 | 27 | 23 pts below |
SNDK has the edge over ICHR on valuation relative to its sector.
ICHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.0 | 19% below |
| 20 week MA | $61.7 | 40% below |
| 50 week MA | $54.6 | 32% below |
| 100 week MA | $38.3 | 3.1% below |
| 200 week MA | $35.8 | 3.5% above |
ICHR has stronger trend alignment. ICHR is above 1 of 5 weekly averages versus SNDK above 0 of 3.
SNDK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,317.5 | 29% below |
| 20 week MA | $1,465.4 | 36% below |
| 50 week MA | $1,119.6 | 16% below |
SNDK is in a downtrend: it's below all three of its weekly moving averages, and 16% below its 50-week average.
ICHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.9 | $30.5 | -10% |
| 2021 | $30.5 | $45.5 | +49% |
| 2022 | $45.5 | $26.2 | -42% |
| 2023 | $26.2 | $33.6 | +28% |
| 2024 | $33.6 | $31.4 | -6.7% |
| 2025 | $31.4 | $19.0 | -40% |
| 2026 YTD | $19.0 | $37.1 | +96% |
ICHR is up 96% so far in 2026, after finishing lower in four of the previous six years.
SNDK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $50.4 | $250.1 | +396% |
| 2026 YTD | $250.1 | $937.5 | +275% |
SNDK has the edge over ICHR on returns for 2026, with the stronger performance.